|
LYN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64146474190829E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66910929522146E-12 |
| Normal-vs-Stage2 |
5.032000E-02 |
| Normal-vs-Stage3 |
1.09160458450219E-11 |
| Normal-vs-Stage4 |
9.97920002188124E-09 |
| Stage1-vs-Stage2 |
6.355400E-04 |
| Stage1-vs-Stage3 |
4.845600E-01 |
| Stage1-vs-Stage4 |
2.749600E-01 |
| Stage2-vs-Stage3 |
4.635900E-04 |
| Stage2-vs-Stage4 |
4.581900E-04 |
| Stage3-vs-Stage4 |
6.216600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
1.416320E-03 |
| Normal-vs-Asian |
6.27359999505472E-08 |
| Caucasian-vs-AfricanAmerican |
5.849600E-01 |
| Caucasian-vs-Asian |
6.610200E-01 |
| AfricanAmerican-vs-Asian |
8.333000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.84150053381427E-10 |
| Normal-vs-Female |
2.17603712826531E-14 |
| Male-vs-Female |
6.307200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.78186412478499E-14 |
| Normal-vs-Age(41-60Yrs) |
4.50628423465105E-12 |
| Normal-vs-Age(61-80Yrs) |
1.5188999999971E-06 |
| Normal-vs-Age(81-100Yrs) |
1.359570E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.673000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.238000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.900000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.772210E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.006600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.958400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.160620E-04 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
3.055600E-02 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.63546953757532E-12 |
| Tall-VS-Other |
6.41149999999202E-05 |
| Tall-VS-Normal |
1.64368518795754E-12 |
| Follicular-VS-Other |
1.814210E-01 |
| Follicular-VS-Normal |
7.209600E-01 |
| Other-VS-Normal |
2.623000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.57799999523212E-08 |
| Normal-vs-N1 |
1.22610000041767E-07 |
| N0-vs-N1 |
7.019000E-03 |
|
|
